vTvT posts Q2 net loss of USD 6.0 million (USD 0.92 per share)

Reuters03-06

vTvT posts <a href="https://laohu8.com/S/QTWO">Q2</a> net loss of USD 6.0 million (USD 0.92 per share)

vTvT reported Q2 2025 results with a net loss attributable to shareholders of USD 6.0 million and a net loss per basic share of USD 0.92. R&D expenses were USD 4.1 million and G&A expenses were USD 3.6 million for the quarter. Cash and cash equivalents totaled USD 25.9 million as of June 30, 2025. On the business side, vTvT said the first participant was randomized in its Phase 3 CATT1 trial of cadisegliatin as an adjunctive therapy to insulin in type 1 diabetes, with topline data expected in the second half of 2026. The company also reported the USPTO allowed claims covering crystalline salt forms of cadisegliatin, with a patent term running through 2041, and noted the May 2025 appointment of Michael Tung as CFO.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617633917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617633917","market":"nz","top_or_hot":-1,"title":"vTvT posts Q2 net loss of USD 6.0 million (USD 0.92 per share)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      vTvT posts <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss of USD 6.0 million (USD 0.92 per share)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        vTvT reported Q2 2025 results with a net loss attributable to shareholders of USD 6.0 million and a net loss per basic share of USD 0.92. R&amp;D expenses were USD 4.1 million and G&amp;A expenses were USD 3.6 million for the quarter. Cash and cash equivalents totaled USD 25.9 million as of June 30, 2025. On the business side, vTvT said the first participant was randomized in its Phase 3 CATT1 trial of cadisegliatin as an adjunctive therapy to insulin in type 1 diabetes, with topline data expected in the second half of 2026. The company also reported the USPTO allowed claims covering crystalline salt forms of cadisegliatin, with a patent term running through 2041, and noted the May 2025 appointment of Michael Tung as CFO.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>vTvT posts Q2 net loss of USD 6.0 million (USD 0.92 per share)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nvTvT posts Q2 net loss of USD 6.0 million (USD 0.92 per share)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-06 21:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      vTvT posts <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss of USD 6.0 million (USD 0.92 per share)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        vTvT reported Q2 2025 results with a net loss attributable to shareholders of USD 6.0 million and a net loss per basic share of USD 0.92. R&amp;D expenses were USD 4.1 million and G&amp;A expenses were USD 3.6 million for the quarter. Cash and cash equivalents totaled USD 25.9 million as of June 30, 2025. On the business side, vTvT said the first participant was randomized in its Phase 3 CATT1 trial of cadisegliatin as an adjunctive therapy to insulin in type 1 diabetes, with topline data expected in the second half of 2026. The company also reported the USPTO allowed claims covering crystalline salt forms of cadisegliatin, with a patent term running through 2041, and noted the May 2025 appointment of Michael Tung as CFO.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL97HLyb:1","article_id":"2617633917","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617633917","pubTimestamp":1772805028,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"vTvT reported Q2 2025 results with a net loss attributable to shareholders of USD 6.0 million and a net loss per basic share of USD 0.92. R&D expenses were USD 4.1 million and G&A expenses were USD 3.6 million for the quarter. Cash and cash equivalents totaled USD 25.9 million as of June 30, 2025. On the business side, vTvT said the first participant was randomized in its Phase 3 CATT1 trial of cadisegliatin as an adjunctive therapy to insulin in type 1 diabetes, with topline data expected in the second half of 2026. The company also reported the USPTO allowed claims covering crystalline salt forms of cadisegliatin, with a patent term running through 2041, and noted the May 2025 appointment of Michael Tung as CFO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VTVT":"vTv Therapeutics Inc."},"translate_title":"vTvT第二季度净亏损600万美元（每股0.92美元）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTVT":0.9},"content_text":"vTvT posts Q2 net loss of USD 6.0 million (USD 0.92 per share)\n    \n\n        vTvT reported Q2 2025 results with a net loss attributable to shareholders of USD 6.0 million and a net loss per basic share of USD 0.92. R&D expenses were USD 4.1 million and G&A expenses were USD 3.6 million for the quarter. Cash and cash equivalents totaled USD 25.9 million as of June 30, 2025. On the business side, vTvT said the first participant was randomized in its Phase 3 CATT1 trial of cadisegliatin as an adjunctive therapy to insulin in type 1 diabetes, with topline data expected in the second half of 2026. The company also reported the USPTO allowed claims covering crystalline salt forms of cadisegliatin, with a patent term running through 2041, and noted the May 2025 appointment of Michael Tung as CFO.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617633917","isCrawlerRequest":true}